{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004734","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.397652+00:00","generated_at":"2026-06-20T18:19:51.432318+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Prime Medicine Announces Preclinical Data and 2023 Strategic Priorities at J.P. Morgan Healthcare Conference","bullets":["New preclinical data in Friedrich's ataxia and cystic fibrosis show restoration of genetic function via Prime Editing.","Preliminary off-target safety analyses in Wilson's disease and CGD detected no guide-dependent editing across 170 and 550 sites, respectively.","PASSIGE technology achieved ~60% precise insertion of a 3.5 kb transgene into primary human T cells in a one-step non-viral process.","LNP delivery to rodent liver achieved >40% editing of PCSK9 gene and >90% reduction in serum PCSK9 protein.","Company expects to nominate first development candidate for CGD in Q1 2023 and file first IND as early as 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004734","json":"https://secwatch.observer/filing/0001193125-23-004734.json","markdown":"https://secwatch.observer/filing/0001193125-23-004734.md","text":"https://secwatch.observer/filing/0001193125-23-004734.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000119312523004734/0001193125-23-004734-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000119312523004734/d448162d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:19:51.432318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}